Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Predictors of 90-day mortality in elderly and unfit AML patients treated with single-agent hypomethylating agents or in combination with venetoclax

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMelissa Francoise NeumannDMDavid MuellerJCJ.M. Cho

Discussion

Loading...

Member takes

Overview

Retrospective cohort study identifies chronic kidney disease and infection as key predictors of early mortality in elderly AML patients treated with hypomethylating agents and venetoclax.

Key Points

  • Overall 90-day mortality reached 34% among 338 elderly AML patients receiving hypomethylating agents and venetoclax.
  • Key predictors included chronic kidney disease and infections requiring hospitalization, impacting treatment outcomes significantly.
  • Retrospective cohort study analyzed clinical and molecular factors across multiple variables to determine mortality risk.
  • Study highlights the importance of identifying specific predictors to enhance personalized care for vulnerable AML populations.

Cite This Study

Neumann et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d608https://doi.org/10.1182/blood-2025-5166
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prolonged venetoclax (VEN) plus hypomethylating agent (HMA) therapy in non-promyelocytic AML: A single-centre retrospective cohort study2025
  2. 2Predictors of early mortality in Acute Myeloid Leukemia: A population based analysis using SEER data.2025
  3. 3Genetic risk model to predict outcomes for AML treated with HMA and venetoclax2025
  4. 4A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium2025
  5. 5Machine learning accurately predicts mortality in adult NPM1-mutant Acute Myeloid Leukemia using baseline clinical and genomic features2025